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Background-—The safety and effectiveness of the fully repositionable LOTUS valve system as compared with the balloon-
expandable Edwards SAPIEN 3 prosthesis for the treatment of aortic stenosis has not been evaluated to date.
Methods and Results-—All patients undergoing transcatheter aortic valve implantation with the Edwards SAPIEN 3 or the LOTUS
valve system were included into the Swiss Transcatheter Aortic Valve Implantation Registry. An adjusted analysis was performed to
compare the early clinical safety outcome according to the Valve Academic Research Consortium-2 deﬁnition. Between February
2014 and September 2015, 140 and 815 patients were treated with the LOTUS and the Edwards SAPIEN 3 valve, respectively.
There was no difference in crude and adjusted analyses of the early safety outcome between patients treated with LOTUS (14.3%)
and those treated with Edwards SAPIEN 3 (14.6%) (crude hazard ratio, 0.97; 95% CI, 0.61–1.56 [P=0.915]; adjusted hazard ratio,
1.03; 95% CI, 0.64–1.67 [P=0.909]). More than mild aortic regurgitation was <2% for both devices. A total of 34.3% of patients
treated with LOTUS and 14.1% of patients treated with Edwards SAPIEN 3 required a permanent pacemaker (HR, 2.76; 95% CI,
1.97–3.87 [P<0.001]).
Conclusions-—The repositionable LOTUS valve system and the balloon-expandable Edwards SAPIEN 3 prosthesis appeared
comparable in regard to the Valve Academic Research Consortium-2 early safety outcome, and the rates of more than mild aortic
regurgitation were exceedingly low for both devices. The need for new permanent pacemaker implantation was more frequent
among patients treated with the LOTUS valve. ( J Am Heart Assoc. 2016;5:e004088 doi: 10.1161/JAHA.116.004088)
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T ranscatheter aortic valve implantation (TAVI) has gainedwide acceptance for the treatment of severe aortic
stenosis among patients deemed to be at increased risk for
surgical aortic valve replacement. Expansion of TAVI to lower
risk patients is critically dependent on the reﬁnement of early-
generation devices to further reduce the risk of paravalvular
regurgitation, device malposition, atrioventricular (AV) con-
ductance disturbances, access-site complications, and peri-
interventional bleeding. Newer-generation devices feature
external cuffs or internal skirts to seal the prosthesis to the
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aortic annulus and reduce the risk of paravalvular regurgita-
tion. Atraumatic, precurved, and steerable delivery catheter
systems aim for a reduction of plaque embolization, and
smaller catheter diameters mitigate the risk of access site
complications and bleeding.1
The LOTUS valve system (Boston Scientiﬁc, Natwick, MA)
is a novel, fully repositionable TAVI prosthesis that permits
evaluation of the ﬁnal conﬁguration of the deployed valve, the
degree of aortic regurgitation, as well as reduced coronary
ﬂow before detachment. Single-arm registries of the LOTUS
valve showed high rates of procedural success and suggested
substantially lower rates of paravalvular regurgitation com-
pared with early-generation devices2–4; conversely, rates of
AV conduction disturbances were relatively high, resulting in
permanent pacemaker implantation in 1 in every fourth
patient up to one in every third patient.2,3
The safety and effectiveness of the fully repositionable
LOTUS valve system as compared with other newer-genera-
tion TAVI devices have not been evaluated to date. We
therefore performed an adjusted comparison of the LOTUS
valve system with the balloon-expandable Edwards SAPIEN 3
prosthesis in patients with aortic stenosis undergoing TAVI
within the nationwide Swiss Transcatheter Aortic Valve
Implantation Registry (NCT01368250).
Methods
Study Population
All patients undergoing TAVI procedures performed in
Switzerland are consecutively captured in a nationwide,
prospective cohort study (ClinicalTrials.gov NCT01368250).5
For the purpose of the present analysis, we investigated all
patients with severe aortic stenosis treated with the
Edwards SAPIEN 3 prosthesis or the LOTUS valve system.
Selection of TAVI candidates, device allocation, and peripro-
cedural management was left to the discretion of the
operators. All data were recorded in a Web-based database
held at the Clinical Trials Unit of the University of Bern,
Switzerland. The Swiss TAVI registry has been approved by
the local cantonal ethics committee and the institutional
review boards of all participating sites. All patients provided
written informed consent for study participation and
prospective follow-up assessment.
Devices
The LOTUS valve system consists of a single nitinol wire that
is braided into a stent frame upon foreshortening and
mechanical expansion. Positioning is facilitated by a radio-
paque marker. The prosthesis is attached to the delivery
system with 3 coupling ﬁngers; buckles at the distal end
connect to posts located at the commissures of the 3 leaﬂets
upon shortening, and lock the valve in its ﬁnal conﬁguration.
The stent frame accommodates a bovine pericardial valve
and comes in 3 prosthesis sizes (23 mm, 25 mm, and
27 mm) ﬁtting an annulus diameter ranging from 20 mm to
26 mm. An adaptive seal in the distal portion of the
prosthesis and an outer sleeve have been designed to
reduce paravalvular regurgitation. The LOTUS prosthesis is
fully repositionable and allows for an assessment of the ﬁnal
result before detachment of the valve from the coupling
ﬁngers of the delivery system. The precurved delivery
catheter has a diameter of 18 F to 20 F and is not steerable.
The valve can be implanted without rapid ventricular
stimulation and predilatation is not necessary in all cases.
The LOTUS valve system received CE mark approval on
October 28, 2013, and on July 14, 2014, for its 23/27 mm
and 25 mm prosthesis, respectively, and since then has
become available for commercial use and implantation in
Switzerland.
The Edwards SAPIEN 3 valve (Edwards Lifesciences, Irvine,
CA) is the fourth iteration of the ﬁrst balloon-expandable
transcatheter aortic valve prosthesis. The stent frame houses
a valve made of 3 modiﬁed pericardial tissue leaﬂets, and
accommodates annulus sizes from 18 mm to 28 mm using 3
device sizes (23 mm, 26 mm, 29 mm). An outer sealing skirt
in the distal portion of the prosthesis complements the inner
PET skirt and aims at a reduction of paravalvular aortic
regurgitation. The prosthesis is loaded on the delivery balloon
in the abdominal aorta rendering the delivery catheter
compatible with 14 F to 16 F. The Commander delivery
catheter is steerable and has a wheel to ﬁne-adjust valve
positioning.6 The Edwards SAPIEN 3 valve was introduced in
Switzerland for implantation on January 27, 2014, and
completely replaced the previously available Edwards SAPIEN
XT prosthesis.
Deﬁnitions
Patients underwent transthoracic echocardiography before
hospital discharge, and were contacted for clinical follow-up
at 30 days. Standardized interviews, documentation from
referring physicians, and hospital discharge summaries were
used for the collection of clinical end points. All end points
were deﬁned according to the updated version of the Valve
Academic Research Consortium (VARC2) deﬁnitions.7 An
independent clinical event committee adjudicated all events.
The prespeciﬁed end point was the VARC2 early safety
outcome, a composite of all-cause mortality, stroke, life-
threatening bleeding, acute kidney injury stage 2 or 3,
coronary obstruction requiring intervention, major vascular
complication, and valve-related dysfunction requiring repeat
procedure.
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Statistical Analysis
Continuous data are reported as meanSD, and categorical
variables are reported as number (percentage) of patients.
Events are reported as counts of ﬁrst occurrence per (sub-)
type of event within 30 days of follow-up (% of all patients).
Event rates at 30 days were compared for patients treated
with the LOTUS versus the Edwards SAPIEN 3 bioprosthesis
using Cox regressions, censoring patients at death or lost to
follow-up. Reported are crude hazard ratios (HRs; with 95%
CIs) with P values from Wald chi-square tests, or continuity
correct risk ratios with P values from Fisher exact tests in
case of zero events. Multiple imputation of missing data was
performed using chained equations (n=20 data sets gener-
ated) before the adjusted analyses. Details on the missing
data are summarized in Table S1. Reported are adjusted HRs
(95% CIs), with the two valves compared, adjusting for age,
dyslipidemia, peripheral vascular disease, aortic regurgitation
moderate or severe, aortic valve area, New York Heart
Association class III or IV, and Society of Thoracic Surgeons
(STS) predicted risk of mortality score. No adjusted analyses
were performed if there were fewer than 5 events overall.
The estimates of adjusted HRs from 20 data sets after
multiple imputation of missing values were combined using
Rubin’s rule and presented with adjusted P values. Two-sided
P values <0.05 were considered statistically signiﬁcant.
Stratiﬁed analyses of the following subgroups were per-
formed: age (≥83 years versus <83 years—median), sex
(female versus male), left ventricular ejection fraction (≤40%
versus >40%), peripheral vascular disease (yes versus no),
STS risk score (>4 versus ≤4), and P value for the
interaction between subgroups and valve type. All analyses
were performed with Stata version 14 (StataCorp, College
Station, TX).
Results
Patient Population
Between February 4, 2014, and September 29, 2015, 140
patients were treated with the LOTUS valve system and 815
patients with the Edwards SAPIEN 3 prosthesis in 12 centers
across Switzerland. Baseline characteristics are summarized
in Table 1. Age, sex, medical history, and cardiovascular risk
factors were well balanced between the two treatment arms.
Compared with patients treated with the LOTUS valve system,
patients treated with the Edward SAPIEN 3 prosthesis more
commonly had peripheral vascular disease (15.5% versus
7.9%, P=0.01) and higher estimated surgical risk as assessed
by the logistic EuroScore (18.914.8% versus 15.08.6%,
P=0.018) and STS score (5.03.8% versus 4.12.4%,
P=0.005).
Procedural Characteristics
Procedural characteristics are shown in Table 2. Although
procedure time was comparable, the amount of contrast
media was greater with the LOTUS valve system compared
with the Edwards SAPIEN 3 prosthesis (17777 mL versus
15393 mL, P=0.004). Patients treated with Edwards
SAPIEN 3 more commonly underwent femoral surgical access
(12.6% versus 5.7%, P=0.018) and predilatation with balloon
valvuloplasty (81.8% versus 31.4%, P<0.001). Device success
was 77.1% among patients treated with the LOTUS valve and
75.7% among patients treated with the Edwards SAPIEN 3
prosthesis (P=0.713). There were no signiﬁcant differences
between the two devices with regards to transprosthetic
gradient, patient prosthesis mismatch, or postprocedural
aortic valve area, respectively (Table 3). Patients treated with
the LOTUS valve more commonly had no aortic regurgitation
after intervention (71.4% versus 53.2%, difference 18.3%; 95%
CI, 9.4–27.1) (Table 2). Whereas 7 patients (0.9%) treated
with the Edwards SAPIEN 3 prosthesis underwent valve in
series implantation due to malpositioning, no case of valve
malpositioning was reported in the LOTUS cohort (P=0.271).
Clinical Outcomes
The early VARC2 safety end point occurred in 14.3% of
patients treated with the LOTUS and 14.6% of patients treated
with the Edwards SAPIEN 3 prosthesis with no difference in
crude (HR, 0.97; 95% CI, 0.61–1.56 [P=0.915]) and adjusted
(HR, 1.03; 95% CI, 0.64–1.67 [P=0.909]) analyses (Figure 1).
Individual components of the primary composite end point are
summarized in Table 3. All-cause mortality at 30 days was
2.2% among patients treated with the LOTUS valve system,
and 2.8% among patients treated with the Edwards SAPIEN 3
valve (adjusted HR, 0.75; 95% CI, 0.22–2.51 [P=0.636]).
Estimated and observed mortality are illustrated in Figure 2.
There were no signiﬁcant differences between the two devices
with regard to mortality, cerebrovascular accidents, myocar-
dial infarction, vascular access site, and bleeding complica-
tions. While none of the patients in the LOTUS group
experienced periprocedural myocardial infarction, 7 patients
treated with the Edwards SAPIEN 3 prosthesis did (0.9%) (HR,
0.39; 95% CI, 0.02–6.79 [P=0.602]).
Despite a higher amount of contrast used in patients
treated with the LOTUS valve, there were no differences with
respect to acute kidney injury. The number of permanent
pacemaker implantations was higher in patients treated with
the LOTUS (34.3%) as compared with the Edwards SAPIEN 3
prosthesis (14.1%) (HR, 2.76; 95% CI, 1.97–3.87 [P<0.001])
(Figure 3). In a stratiﬁed analysis for the VARC2 early safety
outcome, there were no signiﬁcant interactions across major
subgroups, with the exception of a positive effect for
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treatment with the LOTUS valve among patients 83 years and
older (P for interaction=0.030) (Figure 4).
Discussion
The key ﬁndings of our analysis can be summarized as follows.
1. In a nationwide prospective registry of patients undergoing
TAVI, we found no differences for the primary end point,
the early composite safety end point within 30 days
between patients treated with the fully repositionable
LOTUS valve system versus the balloon-expandable
Edwards SAPIEN 3 prosthesis.
2. Rates of device success were comparable for both devices.
3. More than mild residual aortic regurgitation was exceed-
ingly low with both devices.
4. Patients treated with the LOTUS valve system had a 2- to
3-fold increased risk of permanent pacemaker implanta-
tion compared with patients treated with the Edwards
SAPIEN 3 prosthesis.
Table 1. Baseline Characteristics
LOTUS Edwards S3
Difference (95% CI) P ValueN=140 N=815
Age, y 82.975.40 81.926.37 1.05 (0.07 to 2.17) 0.065
Female sex, No. (%) 65 (46.4) 352 (43.2) 3.2% (5.7% to 12.1%) 0.519
Body mass index, kg/m2 26.644.77 26.955.27 0.31 (1.25 to 0.63) 0.516
Cardiac risk factors
Diabetes mellitus, No. (%) 33 (23.6) 200 (24.5) 1.0% (6.8% to 8.7%) 0.915
Dyslipidemia, No. (%) 80 (57.1) 392 (48.1) 9.0% (18.0% to 0.1%) 0.055
Hypertension, No. (%) 114 (81.4) 625 (76.8) 4.6% (12.2%; 2.9%) 0.273
Medical history
Previous pacemaker implantation, No. (%) 15 (10.7) 80 (9.8) 0.9% (6.3% to 4.5%) 0.760
Previous myocardial infarction, No. (%) 21 (15.0) 122 (15.0) 0.0% (6.4% to 6.4%) 1.000
Previous cardiac surgery, No. (%) 14 (10.0) 114 (14.0) 4.0% (2.1% to 10.1%) 0.228
Previous cerebrovascular accident, No. (%) 14 (10.0) 91 (11.2) 1.2% (4.5% to 6.8%) 0.771
Clinical features
Peripheral vascular disease, No. (%) 11 (7.9) 126 (15.5) 7.6% (1.3%–13.9%) 0.018
Chronic obstructive pulmonary disease, No. (%) 11 (7.9) 91 (11.2) 3.3% (2.2% to 8.9%) 0.300
Coronary artery disease, No. (%) 85 (60.7) 477 (58.5) 2.2% (11.0% to 6.7%) 0.643
Left ventricular ejection fraction, % 56.1312.13 55.1414.44 0.98 (1.79 to 3.76) 0.487
Aortic valve area, cm2 0.660.22 0.710.23 0.05 (0.10 to 0.00) 0.046
Mean transvalvular aortic gradient, mm Hg 49.3619.54 46.1421.50 3.22 (0.89 to 7.32) 0.125
Symptoms on admission
NYHA class 0.061
NYHA I or II, No. (%) 58 (41.4) 255 (33.2) 8.2% (0.4% to 16.7%) 0.066
NYHA III or IV, No. (%) 82 (58.6) 512 (66.8) 8.2% (16.7% to 0.4%) 0.066
CCS angina class n=140 n=811 0.508
No angina, No. (%) 113 (80.7) 626 (77.2) 3.5% (4.0% to 11.0%) 0.381
CCS I or II, No. (%) 21 (15.0) 131 (16.2) 1.2% (7.7% to 5.4%) 0.803
CCS III or IV, n (%) 6 (4.3) 54 (6.7) 2.4% (6.7% to 2.0%) 0.349
Risk assessment
Log EuroScore, % 14.958.62 18.8514.78 3.90 (7.14 to 0.67) 0.018
STS score, % 4.102.42 5.043.76 0.93 (1.58 to 0.28) 0.005
Values are expressed as means with SDs (P value from t tests) or counts (% of all patients; P value from Fisher or chi-square tests). CCS indicates Canadian Cardiovascular Society; NYHA,
New York Heart Association; STS, Society of Thoracic Surgeons.
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Newer-generation TAVI devices are characterized by
improved device success as compared with early-generation
devices primarily by a reduction of moderate or severe
prosthetic valve regurgitation, which has consistently been
associated with increased late mortality.8,9 Documentation of
moderate to severe aortic regurgitation has been reported in
up to 14% of patients treated with early-generation devices,8–10
and motivated the development of internal skirts and external
cuffs to seal the prosthesis to the aortic annulus and reduce
paravalvular regurgitation. Complimentary to technical reﬁne-
ments of the devices, dedicated imaging tools have been
introduced allowing for precise device positioning within the
Table 2. Procedural Characteristics
LOTUS Edwards S3
Difference (95% CI) P ValueN=140 N=815
Procedure time, min 69.8126.09 70.2533.47 0.44 (6.40 to 5.52) 0.885
Amount of contrast, mL 177.1077.06 152.5993.34 24.51 (7.78–41.24) 0.004
General anesthesia, No. (%) 35 (25.0) 314 (38.5) 13.5% (22.1% to 4.9%) 0.002
Type of transfemoral access 0.018
Percutaneous, No. (%) 132 (94.3) 712 (87.4) 6.9% (1.2%–12.7%)
Surgical, No. (%) 8 (5.7) 103 (12.6) 6.9% (12.7% to 1.2%)
Concomitant procedure
Percutaneous coronary intervention, No. (%) 12 (8.6) 50 (6.1) 2.4% (6.9% to 2.0%) 0.268
Device features
Valve size
23 mm 44 (31.4%) 216 (26.5%)
25 mm 51 (36.4%)
26 mm 351 (43.1%)
27 mm 45 (32.1%)
29 mm 248 (30.4%)
Prior balloon aortic valvuloplasty, No. (%) 44 (31.4) 667 (81.8) 50.4% (43.3%; 57.6%) <0.001
Device success, No. (%) 108 (77.1%) 617 (75.7%) 1.4% (6.2% to 9.1%) 0.713
Valve in series, No. (%) 0 (0.0%) 7 (0.9%) 0.9% (2.4% to 0.7%) 0.271
Repeat unplanned intervention within 30 days 1 (0.7%) 11 (1.3%) 0.6% (2.6% to 1.4%) 0.533
Patient prosthesis mismatch, No. (%) 0.928
Insignificant 114 (81.4%) 661 (81.1%) 0.3% (6.7% to 7.4%)
Moderate/severe 26 (18.6%) 154 (18.9%) 0.3% (7.4% to 6.7%)
Aortic regurgitation post-TAVI <0.001
Grade 0, No. (%) 100 (71.4) 430 (53.2) 18.3% (9.4%–27.1%)
Grade 1, No. (%) 39 (27.9) 369 (45.6) 17.8% (26.6% to 8.9%)
Grade 2, No. (%) 1 (0.7) 10 (1.2) 0.5% (2.4% to 1.4%)
Grade 3, No. (%) 0 0 na
Postprocedure
Mean transprosthetic gradient, mm Hg 10.296.10 9.515.10 0.79 (0.17 to 1.74) 0.106
Aortic valve area, mm 1.780.61 1.750.53 0.03 (0.10 to 0.16) 0.675
In-hospital course
Any PRBC, No. (%) 11 (7.9) 111 (13.6) 5.8% (0.2% to 11.8%) 0.074
Number of PRBC, median (interquartile range) 2.0 (1.0–4.0) 2.0 (2.0–3.3) 1.85 (0.03–3.68) 0.839
Overall in-hospital stay after TAVI, days 9.344.40 9.475.55 0.13 (1.10 to 0.84) 0.790
Values are expressed as means with standard deviations (P values from t tests) or counts (% of all patients; P values from Fisher tests or chi-square tests). PRBC indicates packed red blood
cell; TAVI, transcatheter aortic valve implantation.
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annular landing zone. In the Swiss TAVI registry, moderate or
severe aortic regurgitation was documented in 0.7% and 1.2%
of patients treated with LOTUS and Edwards SAPIEN 3,
respectively. Our ﬁndings are consistent with the Reposition-
able Percutaneous Replacement of Stenotic Aortic Valve
Through Implantation of Lotus Valve System: Evaluation of
Safety and Performance (REPRISE) II study and the UK LOTUS
registry, reporting moderate or severe aortic regurgitation in
1% and 0.8% of patients, respectively.2,3 Reduction of
paravalvular aortic regurgitation results from a combination
of both, the full repositionability of the LOTUS valve allowing
for an assessment of the result prior to deployment, and the
prosthesis design with an adaptive seal in the distal portion
and an outer sleeve.6 A similarly low incidence of moderate to
severe aortic regurgitation was documented with the Edwards
SAPIEN 3 valve that has been reﬁned by an external sealing
cuff that mimics a parachute. The incidence of more than mild
paravalvular regurgitation decreased from 5.3% to 1.3%
Table 3. Clinical Outcomes at 30 Days
LOTUS Edwards S3
HR (95% CI) P Value Adjusted HR (95% CI)
Adjusted
P ValueN=140 N=815
Early safety primary end point VARC2 20 (14.3) 119 (14.6) 0.97 (0.61–1.56) 0.915 1.03 (0.64–1.67) 0.909
Mortality, No. (%) 3 (2.2) 23 (2.8) 0.75 (0.22–2.49) 0.636 0.75 (0.22–2.51) 0.636
Cardiovascular Mortality, No. (%) 2 (1.5) 21 (2.6) 0.55 (0.13–2.33) 0.414 0.51 (0.12–2.21) 0.371
Cerebrovascular accident, No. (%) 6 (4.3) 25 (3.1) 1.40 (0.57–3.41) 0.461 1.42 (0.57–3.50) 0.448
Disabling stroke, No. (%) 3 (2.1) 9 (1.1) 1.93 (0.52–7.15) 0.322 2.01 (0.53–7.61) 0.304
Nondisabling stroke, No. (%) 3 (2.1) 11 (1.4) 1.58 (0.44–5.68) 0.480 1.59 (0.43–5.79) 0.485
TIA, No. (%) 0 (0.0) 5 (0.6) 0.53 (0.03–9.53) 1.000
MI, No. (%) 0 (0.0) 9 (1.1) 0.31 (0.02–5.30) 0.371
Periprocedural MI, No. (%) 0 (0.0) 7 (0.9) 0.39 (0.02–6.79) 0.602
Spontaneous MI, n (%) 0 (0.0) 2 (0.3) 1.16 (0.06–24.03) 1.000
Acute kidney injury, No. (%) 2 (1.4) 26 (3.2) 0.44 (0.10–1.86) 0.265 0.62 (0.14–2.67) 0.522
Stage 1, No. (%) 1 (0.7) 5 (0.6) 1.16 (0.14–9.94) 0.891 1.06 (0.12–9.55) 0.960
Stage 2, No. (%) 0 (0.0) 6 (0.7) 0.45 (0.03–7.94) 0.600
Stage 3, No. (%) 1 (0.7) 15 (1.9) 0.38 (0.05–2.90) 0.353 0.61 (0.08–4.79) 0.642
Bleeding, No. (%) 17 (12.2) 131 (16.2) 0.74 (0.45–1.23) 0.246 0.79 (0.47–1.32) 0.368
Life-threatening bleeding, No. (%) 6 (4.3) 45 (5.5) 0.77 (0.33–1.81) 0.550 0.79 (0.33–1.87) 0.586
Major bleeding, No. (%) 8 (5.7) 59 (7.3) 0.78 (0.37–1.63) 0.512 0.81 (0.38–1.71) 0.572
Minor bleeding, No. (%) 3 (2.1) 28 (3.5) 0.62 (0.19–2.03) 0.425 0.75 (0.22–2.49) 0.633
Vascular access site and
access-related complications, No. (%)
19 (13.6) 112 (13.8) 0.98 (0.60–1.60) 0.946 0.96 (0.59–1.58) 0.880
Major vascular complications, No. (%) 10 (7.2) 76 (9.3) 0.76 (0.39–1.47) 0.416 0.72 (0.37–1.41) 0.342
Minor vascular complications, No. (%) 8 (5.7) 32 (3.9) 1.45 (0.67–3.16) 0.344 1.45 (0.66–3.19) 0.357
Structural valve deterioration, No. (%) 0 (0.0) 1 (0.1) 1.93 (0.08–47.14) 1.000
Repeat unplanned intervention, No. (%) 1 (0.7) 11 (1.4) 0.52 (0.07–4.04) 0.534 0.38 (0.05–3.04) 0.363
Valve-related dysfunction requiring intervention 0 (0.0) 3 (0.4) 0.83 (0.04–15.98) 1.000
Valve in valve treatment, No. (%) 0 (0.0) 0 (0.0)
Surgical revision, No. (%) 0 (0.0) 3 (0.4) 0.83 (0.04–15.98) 1.000
Other, No. (%) 1 (0.7) 8 (1.0) 0.72 (0.09–5.73) 0.754 0.53 (0.06–4.32) 0.550
Permanent pacemaker implantation, No. (%) 48 (34.3) 113 (14.1) 2.76 (1.97–3.87) <0.001 2.63 (1.86–3.73) <0.001
Depicted are the number of ﬁrst events within 30 days with percentage of all patients. All clinical outcomes were adjudicated, except for pacemaker implantations. Cox regressions
reporting hazard ratios (HRs; with 95% CIs) or continuity corrected risk ratios (95% CIs) in case of zero events with Fisher exact P values. Adjusted HR from Cox regressions, adjusting for
age, dyslipidemia, peripheral vascular disease, aortic regurgitation moderate or severe, aortic valve area, New York Heart Association class III or IV, and Society of Thoracic Surgery risk
score (combining the estimates of 20 data sets using Rubin’s rule because of missing data). Multiple imputation of missing data was performed using chained equations (n=20 data sets
generated). There was no adjusted analyses if there were fewer than 5 events overall. MI indicates myocardial infarction; TIA, transient ischemic attack; VARC2, Valve Academic Research
Consortium.
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(P=0.04) as compared with its predecessor in a previous
analysis from the Swiss TAVI registry including almost 600
patients.11
Rates of permanent pacemaker implantation amounted to
34% among patients treated with the LOTUS valve, and were
2- to 3-fold higher compared with patients treated with the
Edwards SAPIEN 3 prosthesis. Comparable rates of AV
conductance disturbances and permanent pacemaker implan-
tation have been consistently reported in the REPRISE II study
(28.6%) and the UK LOTUS registry (31.8%).2,3 The effect of
permanent pacemaker implantation after TAVI on long-term
outcomes remains a matter of debate.12,13 No difference in
1-year mortality was documented in patients with a previous
permanent pacemaker, a new permanent pacemaker, or no
pacemaker in a prospective registry of 353 patients from 2
institutions.12 In contrast, permanent pacemaker implantation
after TAVI was reported to be an independent predictor of
1-year mortality in an analysis of the Placement of Aortic
Transcatheter Valves (PARTNER I) trial.13 Moreover, perma-
nent pacemaker implantation was associated with a longer
duration of hospitalization and higher rates of repeat hospi-
talization at 1 year.14 The degree of pacemaker dependency
accompanied by ventricular dyssynchrony may reconcile the
differential in clinical ﬁndings between studies. AV conduc-
tance disturbances along with pacemaker dependency after
TAVI may be temporary rather than permanent in nature. In a
small study of 36 patients with new pacemaker following
implantation of a self-expandable prosthesis, more than half
of the patients were pacemaker independent at a median
follow-up of 12 months.15
The rates of the early composite safety end point were
comparable between the two devices at 30 days. In line, there
were no differences with respect to cardiovascular mortality,
myocardial infarction, bleeding, or vascular access site
complications. The observed mortality rate (LOTUS 2.2%
versus SAPIEN 3 2.8%) was substantially lower as compared
with the STS estimates. The overall incidence of stroke was
4.3% and 3.1% of patients treated with the LOTUS valve
system and the Edwards SAPIEN 3 prosthesis, respectively.
The incidence of stroke at 30 days was 5.9% in the REPRISE II
study and 3.9% in the UK LOTUS registry,2,3 while large
nationwide TAVI registries reported stroke rates in the range
Lotus vs Sapien 3: HR (95% CI)=0.97 (0.61–1.56), P=0.915
0
5
10
15
20
25
30
Ea
rly
 S
af
et
y 
VA
R
C
2 
(a
t 3
0 
da
ys
), 
%
140 122 122 120 120 119 110Lotus
815 710 696 688 685 670 634Sapien 3
Number at risk
0 5 10 15 20 25 30
Days Since Valve Procedure
Figure 1. Kaplan–Meier estimates of the Valve Academic
Research Consortium 2 (VARC2) early safety composite outcome
at 30 days. The blue line relates to the LOTUS valve system; the red
line relates to the Edwards SAPIEN 3 valve. HR indicates hazard
ratio.
Figure 2. Bar graph of estimated and observed mortality at 30 days. Society of Thoracic
Surgeons (STS) risk scores were used to estimate mortality at 30 days.
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of 1.5% to 4%.9,11,16–19 Although the signal has to be
interpreted with caution, several reasons may account for a
potential difference in cerebrovascular events between the
two devices. A signiﬁcantly lower rate of prior balloon
valvuloplasty among patients treated with the LOTUS valve
as compared with the Edwards SAPIEN valve may affect the
rates of stroke. In a small study of 87 patients, the volume of
new cerebral ischemic lesions as assessed by diffusion-
weighted magnetic resonance imaging was signiﬁcantly
higher among patients without as compared with patients
with prior balloon aortic valvuloplasty.20 In contrast, a recent
meta-analysis of 18 studies with 2443 patients demonstrated
a trend towards a reduced risk of clinically relevant stroke
with direct TAVI. However, the ﬁndings should be interpreted
with caution given the limitations of the nonrandomized
studies included in the meta-analysis and the unadjusted
nature of the summary measures used.21 The effect of
predilatation on clinical outcome is currently being investi-
gated in the Transcatheter Aortic Valve Implantation Without
Predilatation (SIMPLIFy TAVI) study (NCT 01539746) and the
Balloon Expandable Transcatheter Aortic Valve Implantation
Without Predilatation of Aortic Valve (EASE-IT) study
(NCT02127580). Moreover, differences in the delivery
catheter diameter, ﬂexibility, and steerability may affect the
risk of plaque abrasion in the aortic arch. Finally, full
repositionability of the LOTUS valve may increase the
inclination of repeated prosthesis placement, which, in turn,
has been associated with an increased risk of stroke.22
Study Limitations
The present analysis has several limitations. First, there was
no random allocation to treatment with the LOTUS valve or
the Edwards SAPIEN 3 prosthesis, respectively. Although
baseline characteristics between the two treatment arms
were comparable, we cannot exclude selection of treatment
according to concealed confounders. We used an adjusted
analysis to correct for differences in baseline characteristics.
Lotus vs Sapien 3: HR (95% CI)=2.76 (1.97–3.87), P<0.001
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Figure 3. Kaplan–Meier estimates for permanent pacemaker
implantation within 30 days. The blue line relates to the LOTUS
valve system; the red line relates to the Edwards SAPIEN 3 valve.
HR indicates hazard ratio.
Figure 4. Stratiﬁed analysis for the Valve Academic Research Consortium 2 Early Composite Safety
Outcome (based on crude hazard ratios). LVEF indicates left ventricular ejection fraction; STS, Society of
Thoracic Surgeons.
DOI: 10.1161/JAHA.116.004088 Journal of the American Heart Association 8
LOTUS Versus SAPIEN 3 for TAVI Pilgrim et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on M
ay 19, 2017
http://jaha.ahajournals.org/
D
ow
nloaded from
 
Second, the number of patients included in the analysis was
limited, and the duration of follow-up did not extend beyond
30 days. However, it constitutes the largest series reported to
date and data are consistent with previously reported single-
arm registries. Third, differences in balloon valvuloplasty prior
to device implantation may have confounded the clinical
results. However, our analysis reﬂects routine clinical practice
with the 2 devices by experienced operators. Finally, implan-
tation depth and oversizing have both been associated with an
increased rate of conductance disturbances, respectively.
Neither of which were prospectively documented in our
registry.
Conclusions
In a nationwide registry, no statistical difference was found
between the repositionable LOTUS valve system and the
balloon-expandable Edwards SAPIEN 3 prosthesis with
respect to the VARC2 early safety outcome for the treatment.
Rates of moderate or severe aortic regurgitation are exceed-
ingly low for both devices. The need for new permanent
pacemaker implantation was more frequent among patients
treated with the LOTUS valve.
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Table S1 Missing Baseline Characteristics, Multiple imputation and Adjusted Analyses 
    Nr of missing values Imputed Used to impute*** 
Used for Adjusted Cox's 
Regression 
Nr of patients   N = 955       
            
Age   0  (0.0%) No Yes Yes 
Sex   0  (0.0%) No Yes No 
Body mass index   3  (0.3%) Yes Yes No 
Cardiac Risk Factors           
Diabetes mellitus   0  (0.0%) No Yes No 
Dyslipidemia   0  (0.0%) No Yes Yes 
Hypertension   1  (0.1%) Yes** Yes No 
Past Medical History           
Previous pacemaker implantation   0  (0.0%) No Yes No 
Previous myocardial infarction   0  (0.0%) No Yes No 
Previous cardiac surgery   0  (0.0%) No Yes No 
Previous cerebrovascular accident   0  (0.0%) No Yes No 
Clinical Features           
Peripheral vascular disease   1  (0.1%) Yes** Yes Yes 
Chronic obstructive pulmonary disease 1  (0.1%) Yes** Yes No 
Coronary artery disease   0  (0.0%) No Yes No 
Aortic Valve Area (cm2)   241 (25.2%) Yes Yes Yes 
Mean transaortic gradient   104 (10.9%) Yes Yes No 
Aortic regurgitation grade moderate or severe 65 (6.8%) Yes Yes Yes 
Mitral regurgitation grade moderate or severe 50  (5.2%) Yes Yes No 
Symptoms on admission           
New York Heart Association (NYHA) Functional Class 48  (5.0%) Yes Yes Yes 
Canadian Cardiovascular Society Angina Class 4  (0.4%) Yes Yes No 
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Risk Assessment           
STS Score   22  (2.3%) Yes Yes Yes 
Device           
Device size   0  (0.0%) No Yes No 
Primary Outcome           
Early Safety Endpoint   0  (0.0%) No Yes No 
            
           
** Single imputation with the mode. All other missing values were multiple imputated. 
*** Chained equations. 
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